Solid Biosciences Inc. Common Stock
SLDBSolid Biosciences Inc. is a biotechnology company focused on developing gene therapy and other innovative treatments for Duchenne muscular dystrophy (DMD), a rare genetic neuromuscular disorder. The company's pipeline aims to address the underlying genetic causes of DMD and improve quality of life for patients through advanced therapeutic approaches.
Company News
Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. The therapy aims to restore frataxin protein levels and address neurologic, cardiac, and systemic disease manifestations.
JPMorgan has upgraded Solid Biosciences' stock from Neutral to Overweight, citing the company's promising gene therapy pipeline and the favorable regulatory environment for its products.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Max Rakhlenko upgraded the rating for Planet Fitness, Inc. (NYSE:PLNT) from Hold to Buy, while raising the price target from $6...
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.
